Study Examines Multiple Methods of Testing Driving Impairment after Consuming Cannabis
A recent study reported results from a University of California San Diego Center for Medicinal Cannabis Research study on cannabis consumption and its effects on driving ability.
A study published May 25, 2023 in the journal Clinical Chemistry evaluated the effects of tetrahydrocannabinol (THC) on driving performance (1). The placebo-controlled randomized double-blinded protocol studied 191 participants who were instructed to smoke as much or as little of a THC cigarette that was either a placebo or contained delta-9-tetrahydrocannabinol (1).
“The relationship between blood THC concentrations and crash risk is not established, but there is a clear understanding that THC impairs driving performance in many, but not necessarily all, individuals,” the introduction stated (1). “The question that remains is how to best identify drivers who are impaired by cannabis.”
After smoking, the participants gave blood, oral fluids (OF), and breath samples. Law enforcement officers from the California Highway Patrol or other agencies performed the sobriety tests on the participants and classified them as impaired or not impaired.
“In the largest trial to date involving experienced users smoking cannabis, there was no correlation between THC (and related metabolites/cannabinoids) in blood, OF, or breath and driving performance,” the researchers concluded (1). “Our data support the current practice in many areas of the United States that requires officer observations of impairment along with toxicology testing before prosecuting drivers for being under the influence.”
The researchers suggested evidence for using oral fluids as opposed to blood samples in reducing the likelihood of false accusations of impairment, and stated that more research is needed on the comparison between exams from drug recognitions experts and field sobriety tests (1).
Reference
- Fitzgerald, R. L.; Umlauf, A.; Hubbard, J. A.; Hoffman, M. A.; Sobolesky, P. M.; Ellis, S. E.; Grelotti, D. J.; Suhandynata, R. T.; Huestis, M. A.; Grant, I.; Marcotte, T. D. Driving under the Influence of Cannabis: Impact of Combining Toxicology Testing with Field Sobriety Tests. Clinical Chemistry 2023.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
